In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
Researchers conducted qualitative interviews to understand patients’ experiences with and perceptions of zuranolone, an oral, investigational, once-daily, 14-day treatment course in clini...
This safety analysis evaluated the duration of treatment-emergent adverse events (TEAEs) reported for esketamine nasal spray (ESK-NS) versus quetiapine extended release (QTP-XR) in patien...
This large, cross-sectional, observational study will be conducted in a sample reflecting bipolar I disorder prevalence in real-world settings to confirm the performance of the Rapid Mood...
Zuranolone 50 mg initiated alone (WATERFALL Study) or co-initiated with a standard-of-care antidepressant (CORAL Study) was well-tolerated in adults with major depressive disorder. In WAT...
The Pathway Platform supports MBC for patients with MDD by integrating a patient-facing app with EHR. This real-world Pathway Platform implementation study in primary care demonstrated si...
This research examined real-world safety data for esketamine nasal spray (ESK) for the first 46 months after product approval, with a focus on adverse events (AEs) of interest (i.e., seda...
This qualitative research study assessed the patient experience of anhedonia and its impacts among patients with MDD. Semi-structured concept elicitation interviews were conducted with 1...